DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia

Leukemia. 2012 May;26(5):1106-7. doi: 10.1038/leu.2011.342. Epub 2011 Nov 29.
No abstract available

Publication types

  • Letter

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antimetabolites, Antineoplastic / therapeutic use*
  • Azacitidine / analogs & derivatives*
  • Azacitidine / therapeutic use
  • DNA (Cytosine-5-)-Methyltransferases / genetics*
  • Decitabine
  • Female
  • Humans
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Middle Aged
  • Mutation*

Substances

  • Antimetabolites, Antineoplastic
  • Decitabine
  • DNA (Cytosine-5-)-Methyltransferases
  • DNA methyltransferase 3A
  • Azacitidine